Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Onyx Pharmaceuticals reports phase III regorafenib data

April 4, 2012

Phase III palifosfamide study advances

April 4, 2012

Hutchinson MediPharma presents potent dual PI3K/mTOR inhibitor

April 4, 2012

First stage of phase III study of Reolysin completes enrollment

April 4, 2012

FORMA Therapeutics presents novel Nampt inhibitors

April 4, 2012

AZD-8055 analogue shows promise to treat of hormone therapy-resistant tumors

April 4, 2012

PolyTherics and Spirogen to collaborate on novel ADCs for cancer

April 3, 2012

Keryx Biopharmaceuticals reports topline data from X-PECT

April 3, 2012

Encouraging data on multikinase inhibitor support clinical development

April 3, 2012

Novel protein kinase inhibitors patented by Suzhou Ascepion Pharmaceuticals

April 3, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...